Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01588951 · ClinicalTrials.gov registry record · Phase 2
Consolidation Therapy for Acute Myeloid Leukemia Guided by Leukemia Stem Cell Behavior
A Phase 2 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Terminated
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT01588951 is a Phase 2 study that was terminated before completion, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 10 participants.
The verdict
NCT01588951, a Phase 2 study, was terminated before completion, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
The primary objective of the trial is to compare the two-year relapse-free survival (RFS) of patients with acute myeloid leukemia (AML), presumed to be at high risk for relapse due to the presence of leukemia stem cells (LSCs) in their bone marrow at first complete remission (CR1), who receive either standard cytarabine-based chemotherapy or allogeneic stem cell transplantation (SCT).
Interventions
- DRUG Cytarabine consolidation
- DRUG Allogeneic transplant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2013-12 |
| Est. Completion | 2017-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01588951
The ClinicalTrials.gov registry entry for NCT01588951 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cytarabine consolidation is the first listed.
NCT01588951 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01588951 about?
NCT01588951 is a clinical study titled "Consolidation Therapy for Acute Myeloid Leukemia Guided by Leukemia Stem Cell Behavior". The primary objective of the trial is to compare the two-year relapse-free survival (RFS) of patients with acute myeloid leukemia (AML), presumed to be at high risk for relapse due to the presence of leukemia stem cells (LSCs) in their bone marrow at first complete remission (CR1), who receive eithe...
What is the current status of trial NCT01588951?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2013-12. Estimated completion is 2017-04.
What interventions are being tested in trial NCT01588951?
The interventions under investigation include: Cytarabine consolidation (DRUG), Allogeneic transplant (DRUG).
Who is sponsoring clinical trial NCT01588951?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.